Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eric Mindich’s and Eton Park’s New Stock Picks

Eric Mindich left Goldman Sachs as Sr. Strategy Officer in 2004 to found Eton Park Capital Management. Mindich had been working at Goldman since he was in high school. He continued working there during the summers at Harvard, where he got an economics degree. He graduated summa cum laude in 1988 from Harvard with a degree in economics. When Mindich was 27, he became a the youngest partner in the history of Goldman.

ETON PARK CAPITAL

Mindich found Eton Park with $3 Billion in investments. Clients had to commit at least $5 million, and that for 4½ years to avoid a 6% redemption fee. The classic 2 and 20 was also applied.

Mindich initiated positions in 13 stocks in the second quarter. Eton Park has $240 Million in iShares Emerging Markets ETF calls (EEM), $180 Million in eBay calls (EBAY), $170 Million in Apple (AAPL), $140 Million in iShares Emerging Markets ETF puts (EEM), $100 Million in Viacom (VIAB), $94 Million in Ralcorp Holdings (RAH), $90 Million in Tyco International (TYC), $64 Million in Vale calls (VALE), about $50 Million each in Huntington Ingalls (HII) and Electronic Arts (ERTS), about $40 Million each in Southern Union (SUG) and Fortune Brands (FO), and $27 Million in Cobalt International Energy (CIE).

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!